Expressions of HER2 and Topo IIα in breast cancer and
its clinical significance.
- Author:
Ping SHUAI
1
Author Information
1. Department of Pathology, Gannan Medical College, Ganzhou Jiangxi 341000, China shuaiping11w@sina.com.
- Publication Type:Journal Article
- MeSH:
Anthracyclines;
pharmacology;
therapeutic use;
Antibiotics, Antineoplastic;
Breast Neoplasms;
chemistry;
genetics;
therapy;
DNA Topoisomerases, Type II;
physiology;
Female;
Humans;
Immunohistochemistry;
In Situ Hybridization, Fluorescence;
Neoadjuvant Therapy;
Receptor, ErbB-2;
physiology;
Treatment Outcome
- From:
Journal of Central South University(Medical Sciences)
2016;41(11):1143-1147
- CountryChina
- Language:Chinese
-
Abstract:
To detect the expressions of human epidermal growth factor receptor 2 (HER2) and Topo IIα in breast cancer, and to analyze the clinical significance of neoadjuvant chemotherapy for the anthracycline-based drugs.
Methods: The HER2 and Topo IIα gene and protein expressions in cancer tissues from 189 patients with breast cancer were detected by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). And the objective response rate (ORR) and pathological complete rate (pCR) were analyzed.
Results: The HER2 protein expression in 46 patients (24.3%) and Topo IIα protein expression in 55 patients (29.1%) was 3+ by IHC or they were 49 (25.9%) and 94 (49.0%) by FISH, respectively. The ORR and pCR in HER2 negative or positive patients were 47.4% and 20.3% or 32.7% and 16.3%, respectively, with significant differences (All P<0.05). The ORR and pCR in Topo IIα positive or negative patients were 69.1% and 36.0% or 28.4% and 2.2%, respectively, with significant differences (All P<0.05).
Conclusion: FISH and IHC were consistent in the determination of HER2 expression whereas they were inconsistent in the determination of Topo IIα expression. The amplification of Topo IIα can effectively improve the effect of the adjuvant treatment effect of the anthracyclines.
